Kiran Mazumdar Shaw said, Remadeivir scarcity will be overcome in second week of May, increasing production capacity of Biocon

Kiran Mazumdar Shaw, executive chairman of Biocon, assured that the shortage of Remedisvir would be removed by mid-May.

Kiran Mazumdar Shaw, executive chairman of Biocon, assured that the shortage of Remedisvir would be removed by mid-May.

Biocon executive chairperson Kiran Mazumdar Shaw hoped that by the end of the second week of May (Mid May), the shortage of Remdesivir in the country would be overcome. He said that this would help in dealing with the second wave of Covid-19 in India (Second Wave of Covid-19).

New Delhi. In the country, the measures to deal with it are also being accelerated amidst the fast growing cases of Corona Crisis in India. Where some companies are providing every thousand metric tons of medical oxygen to the country. At the same time, the production of medicines considered to be effective in the treatment of corona infection is also being increased. In this series, Kiran Mazumdar Shaw, the head of the pharma company Biocon, said that the company’s production capacity is being increased to overcome shortage of Remdesivir. ‘Will help to deal with second wave of Kovid-19’ Kiran Mazumdar Shaw, executive chairman of Biocon, hoped that by the end of the second week of May (Mid May), the shortage of this drug in the country would be overcome. He said that this would help in dealing with the second wave of Covid-19 in India (Second Wave of Covid-19). Please tell that doctors are considering Remedesvir as the most effective drug in the treatment of corona patients. At the same time, the production of this medicine was stopped in January and February because it cannot be preserved for more days by making it. read this also- Gold Price Today: Gold prices today rose marginally, silver prices increased sharply, see new prices quicklyGenentech Lifesciences is also producing Remedisvir Union Minister Nitin Gadkari also said on 27 April that the pharmaceuticals company Genentech Lifesciences in Wardha, Maharashtra will start production of Remadecivir Injection from 28 April. He said that the company will prepare 30,000 vials of Remedisvir daily. Explain that the limited use of Remedicivir has been approved in the suspected patients of Kovid-19 admitted in hospitals in the country and adult patients and children confirmed through lab report. Genentech Life Sciences of Wardha has been licensed for the manufacture of ramdescivir injection.




Leave a Reply

Your email address will not be published. Required fields are marked *